BeiGene (NASDAQ:BGNE)’s share price reached a new 52-week high and low on Monday . The stock traded as low as $194.70 and last traded at $192.37, with a volume of 17024 shares changing hands. The stock had previously closed at $179.79.
BGNE has been the topic of several research analyst reports. Maxim Group lifted their target price on BeiGene from $160.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, April 10th. Ladenburg Thalmann reaffirmed a “buy” rating and set a $172.00 target price on shares of BeiGene in a research note on Thursday, March 1st. They noted that the move was a valuation call. BidaskClub raised BeiGene from a “hold” rating to a “buy” rating in a research note on Wednesday, January 31st. Zacks Investment Research raised BeiGene from a “hold” rating to a “buy” rating and set a $190.00 target price on the stock in a research note on Tuesday, May 1st. Finally, Robert W. Baird reaffirmed a “hold” rating and set a $138.00 target price on shares of BeiGene in a research note on Thursday, March 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. BeiGene presently has a consensus rating of “Buy” and a consensus target price of $169.43.
The company has a market cap of $10.06 billion, a P/E ratio of -83.85 and a beta of 0.29. The company has a debt-to-equity ratio of 0.12, a current ratio of 11.18 and a quick ratio of 11.12.
BeiGene (NASDAQ:BGNE) last announced its quarterly earnings results on Wednesday, May 9th. The company reported ($2.03) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.62) by ($0.41). The company had revenue of $32.54 million during the quarter, compared to analyst estimates of $16.88 million. During the same period last year, the firm posted ($1.27) earnings per share. equities analysts anticipate that BeiGene will post -8.23 earnings per share for the current year.
In related news, CEO John Oyler sold 99,000 shares of the business’s stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $145.63, for a total value of $14,417,370.00. Following the completion of the sale, the chief executive officer now owns 93,883 shares of the company’s stock, valued at approximately $13,672,181.29. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Howard Liang sold 40,000 shares of the business’s stock in a transaction that occurred on Monday, March 19th. The stock was sold at an average price of $160.27, for a total value of $6,410,800.00. Following the completion of the sale, the chief financial officer now owns 15,872 shares of the company’s stock, valued at $2,543,805.44. The disclosure for this sale can be found here. In the last three months, insiders sold 194,210 shares of company stock valued at $29,041,676. 19.90% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Quantbot Technologies LP acquired a new stake in BeiGene in the 1st quarter worth approximately $290,000. Northern Trust Corp acquired a new stake in BeiGene in the 1st quarter worth approximately $302,000. Tower Research Capital LLC TRC acquired a new stake in BeiGene in the 4th quarter worth approximately $182,000. Comerica Bank acquired a new stake in BeiGene in the 4th quarter worth approximately $246,000. Finally, Mackenzie Financial Corp acquired a new stake in BeiGene in the 4th quarter worth approximately $250,000. Hedge funds and other institutional investors own 51.88% of the company’s stock.
BeiGene Company Profile
BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.